321 related articles for article (PubMed ID: 19875192)
1. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
Li J; Li ZN; Yu LC; Bao QL; Wu JR; Shi SB; Li XQ
Lung Cancer; 2010 Jul; 69(1):116-22. PubMed ID: 19875192
[TBL] [Abstract][Full Text] [Related]
2. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
[TBL] [Abstract][Full Text] [Related]
3. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy.
Li XQ; Li J; Shi SB; Chen P; Yu LC; Bao QL
Int J Biol Markers; 2009; 24(4):230-7. PubMed ID: 20082278
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
[TBL] [Abstract][Full Text] [Related]
5. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
[TBL] [Abstract][Full Text] [Related]
6. Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Rijavec M; Silar M; Triller N; Kern I; Cegovnik U; Košnik M; Korošec P
Pathol Oncol Res; 2011 Sep; 17(3):691-6. PubMed ID: 21455636
[TBL] [Abstract][Full Text] [Related]
7. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
Kim YH; Ishii G; Goto K; Ota S; Kubota K; Murata Y; Mishima M; Saijo N; Nishiwaki Y; Ochiai A
Lung Cancer; 2009 Jul; 65(1):105-11. PubMed ID: 19036469
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
9. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.
Diestra JE; Condom E; Del Muro XG; Scheffer GL; Pérez J; Zurita AJ; Muñoz-Seguí J; Vigués F; Scheper RJ; Capellá G; Germà-Lluch JR; Izquierdo MA
J Urol; 2003 Oct; 170(4 Pt 1):1383-7. PubMed ID: 14501774
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P
Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
12. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
14. Expression of efflux transporters in human ocular tissues.
Chen P; Chen H; Zang X; Chen M; Jiang H; Han S; Wu X
Drug Metab Dispos; 2013 Nov; 41(11):1934-48. PubMed ID: 23979916
[TBL] [Abstract][Full Text] [Related]
15. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
[TBL] [Abstract][Full Text] [Related]
16. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
van den Heuvel-Eibrink MM; van der Holt B; Burnett AK; Knauf WU; Fey MF; Verhoef GE; Vellenga E; Ossenkoppele GJ; Löwenberg B; Sonneveld P
Ann Hematol; 2007 May; 86(5):329-37. PubMed ID: 17340137
[TBL] [Abstract][Full Text] [Related]
17. [Predictive value of drug resistance-related genes expression in neoadjuvant chemotherapy in patients with non-small cell lung cancer of stage III].
Peng ZM; Luo J; Wang WB; Wang XH; Chen JH; Lan SM
Ai Zheng; 2004 Aug; 23(8):963-7. PubMed ID: 15301725
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
[TBL] [Abstract][Full Text] [Related]
19. [Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].
Katsaros D; Fracchioli S; Arts HJ; de Vries EG; Danese S; Richiardi G; Arisio R; Gordini G; Van der Zee AG; Suurmeijer AJ; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):463-70. PubMed ID: 10767994
[TBL] [Abstract][Full Text] [Related]
20. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
